The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma

Clinical Oncology

Volumn 15, Issue 7, 2003, Pages 400-407

  Wilson, David ^a   Hiller, L ^b   Gray, L ^b   Grainger, M ^c   Stirling, A ^c   James, N ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

Metastases; Radiotherapy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BRAIN METASTASIS; CALCULATION; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYMPTOM; TIME;

EID: 0141519594     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(03)00164-X     Document Type: Article

References (33)

1. DeVita V, Hellman S, Rosenberg SA. Cancer. Principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins.
2. Saitoh H. Distant metastases of renal adenocarcinoma. Cancer 1981;48:1487-1491.
3. Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 1985; 11:2007-2009.
4. DiBiase SJ, Valcenti RK, Schultz D, et al. Palliative irradiation for focally symptomatic metastatic renal cell adenocarcinoma: support for dose escalation based on a biological model. J Urol 1997; 158:746-749.
5. Halperin EC, Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 1983; 51:614-617.
6. Fowler JF. Biological factors influencing optimum fractionation in radiation treatment. Acta Oncol 2001;40:712-717.
7. Ning S, Trisler K, Wessels BW, et al. Radiobiological studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997; 80:2519-2528.
8. Jones B, Dale RG, Deehan C, et al. The role of biological effective dose (BED) in clinical oncology. Clin Oncol 2001;13:71-81.
9. Fowler JF. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-694.
10. Seitz W, Karcher KH, Binder W. Radiotherapy of metastatic renal cell carcinoma. Semin Surg Oncol 1988;4:100-102.
11. Leung SW, Mitchell JB, al-Nabulsi I, et al. Effect of L-butathione sulfoximine on the radiation response of human renal carcinoma cell lines. Cancer 1993;71:2276-2285.
12. Syljuasen RG, Belldegrun A, Tso CL, et al. Sensitization of renal carcinoma to radiation using alpha interferon gene transfection. Radiat Res 1997;148:443-448.
13. Huguenin PU, Kieser S, Glanzmann C, et al. Radiotherapy for metastatic carcinoma of the kidney or melanomas: an analysis using palliative end points. Int J Radiat Oncol Biol Phys 1998; 41:401-405.
14. Maldazys JD, deKernion JB. Prognostic factors in metastatic renal cell carcinoma. J Urol 1986;136:376-379.
15. Dale RG. Time-dependant tumour repopulation factors in the linear quadratic equations: implications for treatment strategies. Radiother Oncol 1989;15:371-382.
16. Jones B, Dale RG, Finst P, et al. Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1379-1384.
17. Quesada JR, Rios A, Swanson D. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985;3:1522-1558.
18. Quesada JR, Swanson D, Gutterman JU. Phase II study of interferon alpha in metastatic renal cell carcinoma: a progress report. J Clin Oncol 1985;3:1086-1092.
19. Quesada JR. Role of interferons in the therapy of metastatic renal cell carcinoma. Urology 1989;34(suppl 4):80-83.
20. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Cancer 1982;50:893-899.
21. Hoskin PJ, Yarnold JR, Roos DR, et al. Consensus statement: radiotherapy for bone metastases. Clin Oncol 2001;13:88-89.
22. Papatheofanis FJ. Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostatic bony metastases. Br J Radiol 1997;70:594-598.
23. Hoskin PJ, Stratford MR, Folkes LK, et al. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet 2000;355:1428-1429.
24. West J, Maor M. Intracranial metastases: behavioural patterns related to primary site and results of treatment with whole brian irradiation. Int J Radiat Oncol Biol Phys 1980;6:11-15.
25. Gelber RD, Larson M, Borgelt BB, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favourable prognosis. Cancer 1981;48:1749-1753.
26. Maor M, Frias AE, Oswald MJ. Palliative radiotherapy for brain metastases in renal carcinoma. Cancer 1988;62:1912-1917.
27. Goyal LK, Suh JH, Reddy CA, et al. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 47:1007-1012.
28. Sioutos PJ, Arbit E, Meshulam CF, et al. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer 1995; 76:1453-1459.
29. Klekamp J, Samii H. Surgical results for spinal metastases. Acta Neurochir 1998;140:957-967.
30. Rades D, Blach M, Nerreter V, et al. Metastatic spinal cord compression. Influence of time between onset of motoric deficits and start of irradiation on therapeutic effect. Strahlenther Onkol 1999;175:378-381.
31. Stirling AJ, Grainger MF, McGee AM. Spinal metastases from renal carcinoma. Conference Proceeding, Key Advances in Renal Carcinoma, London, 2001.
32. Wise JJ, Fischgrund JS, Herkowitz HN, et al. Complications, survival rates, and risk factor of surgery for metastatic disease of the spine. Spine 1999;24:1943-1951.
33. Jackson RJ, Gokaslan ZL, Loh S-CA. Metastatic renal cell carcinoma of the spine: surgical treatment and results. J Neurosurg 2001;94(suppl 1):18-24.